A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
Oh, Crystal Yuri
Albrecht, Randy A
Nilsson-Payant, Benjamin E
Kim, Seong Min
Zhu, Danni Y
Benam, Kambez H
Gilpin, Sarah E
Gygi, Steven P
Powers, Rani K
Carlson, Kenneth E
tenOever, Benjamin R
Ingber, Donald E
JournalNature Biomedical Engineering
MetadataShow full item record
AbstractThe rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells. In airway chips infected with influenza A, the co-administration of nafamostat with oseltamivir doubled the treatment-time window for oseltamivir. In chips infected with pseudotyped severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), clinically relevant doses of the antimalarial drug amodiaquine inhibited infection but clinical doses of hydroxychloroquine and other antiviral drugs that inhibit the entry of pseudotyped SARS-CoV-2 in cell lines under static conditions did not. We also show that amodiaquine showed substantial prophylactic and therapeutic activities in hamsters challenged with native SARS-CoV-2. The human airway-on-a-chip may accelerate the identification of therapeutics and prophylactics with repurposing potential.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15665
- Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
- Authors: Andrew M, Jayaraman G
- Issue date: 2021 Jul
- Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
- Authors: Mirabelli C, Wotring JW, Zhang CJ, McCarty SM, Fursmidt R, Pretto CD, Qiao Y, Zhang Y, Frum T, Kadambi NS, Amin AT, O'Meara TR, Spence JR, Huang J, Alysandratos KD, Kotton DN, Handelman SK, Wobus CE, Weatherwax KJ, Mashour GA, O'Meara MJ, Chinnaiyan AM, Sexton JZ
- Issue date: 2021 Sep 7
- The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
- Authors: Santopolo S, Riccio A, Santoro MG
- Issue date: 2021 Jan 29
- Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
- Authors: Park SJ, Yu KM, Kim YI, Kim SM, Kim EH, Kim SG, Kim EJ, Casel MAB, Rollon R, Jang SG, Lee MH, Chang JH, Song MS, Jeong HW, Choi Y, Chen W, Shin WJ, Jung JU, Choi YK
- Issue date: 2020 May 22
- AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 <i>In Vitro</i> and a Promising Oral Antiviral for Treatment of COVID-19.
- Authors: Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P, Collu G, Canard B, Sommadossi JP
- Issue date: 2021 Mar 18